About this Journal Submit a Manuscript Table of Contents
ISRN Endocrinology
Volume 2012 (2012), Article ID 240634, 12 pages
http://dx.doi.org/10.5402/2012/240634
Review Article

Insulin Therapy and Cancer in Type 2 Diabetes

Agenzia Diabetologia, Ponte Nuovo, Ospedale di Careggi, Via delle Oblate, 4-50141 Firenze, Italy

Received 13 September 2012; Accepted 3 October 2012

Academic Editors: J. A. Rillema and G. F. Wagner

Copyright © 2012 Edoardo Mannucci. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. H. Zhou, Q. Qiao, B. Zethelius et al., “Diabetes, prediabetes and cancer mortality,” Diabetologia, vol. 53, no. 9, pp. 1867–1876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. X. Yang, G. T. C. Ko, W. Y. So et al., “Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry,” Diabetes, vol. 59, no. 5, pp. 1254–1260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Wang, D. Kang, W. Cao, Y. Wang, and Z. Liu, “Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis,” Diabetes/Metabolism Research and Reviews, vol. 28, no. 2, pp. 109–122, 2012.
  4. D. Li, H. Tang, M. M. Hassan, E. A. Holly, P. M. Bracci, and D. T. Silverman, “Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies,” Cancer Causes and Control, vol. 22, no. 2, pp. 189–197, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Jiang, Q. Ben, H. Shen, W. Lu, Y. Zhang, and J. Zhu, “Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies,” European Journal of Epidemiology, vol. 26, no. 11, pp. 863–876, 2011.
  6. Z. Ge, Q. Ben, J. Qian, Y. Wang, and Y. Li, “Diabetes mellitus and risk of gastric cancer: a systematic review and meta-analysis of observational studies,” European Journal of Gastroenterology & Hepatology, vol. 23, no. 12, pp. 1127–1135, 2011.
  7. J. Mitri, J. Castillo, and A. G. Pittas, “Diabetes and risk of non-hodgkin's lymphoma: a meta-analysis of observational studies,” Diabetes Care, vol. 31, no. 12, pp. 2391–2397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Liao, J. Li, W. Wei et al., “Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 4, pp. 1061–1065, 2011.
  9. S. Bonovas, K. Filioussi, and A. Tsantes, “Diabetes mellitus and risk of prostate cancer: a meta-analysis,” Diabetologia, vol. 47, no. 6, pp. 1071–1078, 2004. View at Scopus
  10. K. Machida, C. L. Chen, J. C. Liu et al., “Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus,” Journal of Gastroenterology and Hepatology, vol. 27, supplement 2, pp. 19–22, 2012.
  11. J. T. Magruder, D. Elahi, and D. K. Andersen, “Diabetes and pancreatic cancer: chicken or egg?” Pancreas, vol. 40, no. 3, pp. 339–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, and R. Vigneri, “Diabetes and cancer,” Endocrine-Related Cancer, vol. 16, no. 4, pp. 1103–1123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Giovannucci, D. M. Harlan, M. C. Archer et al., “Diabetes and cancer: a consensus report,” Diabetes Care, vol. 33, no. 7, pp. 1674–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Müssig, H. Staiger, K. Kantartzis, A. Fritsche, L. Kanz, and H. U. Häring, “Type2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?” Diabetic Medicine, vol. 28, no. 3, pp. 276–286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Soranna, L. Scotti, A. Zambon et al., “Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis,” Oncologist, vol. 17, no. 6, pp. 813–822, 2012. View at Publisher · View at Google Scholar
  16. Z. J. Zhang, Z. J. Zheng, R. Shi, Q. Su, Q. Jiang, and K. E. Kip, “Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis,” Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 7, pp. 2347–2353, 2012. View at Publisher · View at Google Scholar
  17. P. D. Home, S. E. Kahn, N. P. Jones, D. Noronha, H. Beck-Nielsen, and G. Viberti, “Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials,” Diabetologia, vol. 53, no. 9, pp. 1838–1845, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Lamanna, M. Monami, N. Marchionni, and E. Mannucci, “Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials,” Diabetes, Obesity and Metabolism, vol. 13, no. 3, pp. 221–228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Azoulay, H. Yin, K. B. Filion et al., “The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study,” British Medical Journal, vol. 344, Article ID e3645, 2012. View at Publisher · View at Google Scholar
  20. I.N. Colmers, S.L. Bowker, S.R. Majumdar, and J.A. Johnson, “Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis,” Canadian Medical Association Journal, vol. 184, no. 12, pp. E675–E683, 2012. View at Publisher · View at Google Scholar
  21. M. Pollak, “The insulin and insulin-like growth factor receptor family in neoplasia: an update,” Nat Rev Cancer, vol. 12, no. 3, pp. 159–169, 2012.
  22. J. C. Heuson, N. Legros, and R. Heimann, “Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats.,” Cancer Research, vol. 32, no. 2, pp. 233–238, 1972. View at Scopus
  23. C. K. Osborne, G. Bolan, M. E. Monaco, and M. E. Lippman, “Hormone responsive human breast cancer in long term tissue culture: effect of insulin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 73, no. 12, pp. 4536–4540, 1976. View at Scopus
  24. E. J. Gallagher and D. LeRoith, “Minireview: IGF, insulin, and cancer,” Endocrinology, vol. 152, no. 7, pp. 2546–2551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Kaaks and A. Lukanova, “Energy balance and cancer: the role of insulin and insulin-like growth factor-I,” Proceedings of the Nutrition Society, vol. 60, no. 1, pp. 91–106, 2001. View at Scopus
  26. L. M. Shaw, “The insulin receptor substrate (IRS) proteins: at the intersection of metabolism and cancer,” Cell Cycle, vol. 10, no. 11, pp. 1750–1756, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. I. F. Godsland, “Insulin resistance and hyperinsulinaemia in the development and progression of cancer,” Clinical Science, vol. 118, no. 5, pp. 315–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Reiss, L. Del Valle, A. Lassak, and J. Trojanek, “Nuclear IRS-1 and cancer,” Journal of Cellular Physiology, vol. 227, no. 8, pp. 2992–3000, 2012. View at Publisher · View at Google Scholar
  29. L. Sciacca, M. F. Cassarino, M. Genua et al., “Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling,” Diabetologia, vol. 53, no. 8, pp. 1743–1753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Corbould, H. Zhao, S. Mirzoeva, F. Aird, and A. Dunaif, “Enhanced mitogenic signaling in skeletal muscle of women with polycystic ovary syndrome,” Diabetes, vol. 55, no. 3, pp. 751–759, 2006. View at Scopus
  31. Y. X. Yang, S. Hennessy, and J. D. Lewis, “Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients,” Gastroenterology, vol. 127, no. 4, pp. 1044–1050, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson, “Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin,” Diabetes Care, vol. 29, no. 2, pp. 254–258, 2006. View at Scopus
  33. M. Monami, C. Lamanna, L. Pala et al., “Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 3, pp. 184–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. C. J. Currie, C. D. Poole, and E. A. M. Gale, “The influence of glucose-lowering therapies on cancer risk in type 2 diabetes,” Diabetologia, vol. 52, no. 9, pp. 1766–1777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. L. G. Hemkens, U. Grouven, R. Bender et al., “Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study,” Diabetologia, vol. 52, no. 9, pp. 1732–1744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Li, S. J. Yeung, M. M. Hassan, M. Konopleva, and J. L. Abbruzzese, “Antidiabetic therapies affect risk of pancreatic cancer,” Gastroenterology, vol. 137, no. 2, pp. 482–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. D. M. Baur, J. Klotsche, O. P. R. Hamnvik et al., “Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort,” Metabolism, vol. 60, no. 10, pp. 1363–1371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Bodmer, C. Becker, C. Meier, S. S. Jick, and C. R. Meier, “Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis,” American Journal of Gastroenterology, vol. 107, no. 4, pp. 620–626, 2012. View at Publisher · View at Google Scholar
  39. T. P. van Staa, D. Patel, A. M. Gallagher, and M. L. de Bruin, “Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data,” Diabetologia, vol. 55, no. 3, pp. 654–665, 2012. View at Publisher · View at Google Scholar
  40. H. M. Colhoun, “Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group,” Diabetologia, vol. 52, no. 9, pp. 1755–1765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. M. M. Hassan, S. A. Curley, D. Li et al., “Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma,” Cancer, vol. 116, no. 8, pp. 1938–1946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. L. C. Vinikoor, M. D. Long, T. O. Keku, C. F. Martin, J. A. Galanko, and R. S. Sandler, “The association between diabetes, insulin use, and colorectal cancer among Whites and African Americans,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 4, pp. 1239–1242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. C. H. Tseng, “Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan,” Diabetologia, vol. 54, no. 8, pp. 2009–2015, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Janghorbani, M. Dehghani, and M. Salehi-Marzijarani, “Systematic review and meta-analysis of insulin therapy and risk of cancer,” Hormones and Cancer, vol. 3, no. 4, pp. 137–146, 2012. View at Publisher · View at Google Scholar
  45. J. M. Jonasson, R. Ljung, M. Talbäck, B. Haglund, S. Gudbjörnsdòttir, and G. Steineck, “Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden,” Diabetologia, vol. 52, no. 9, pp. 1745–1754, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Monami, C. Lamanna, D. Balzi, N. Marchionni, and E. Mannucci, “Sulphonylureas and cancer: a case-control study,” Acta Diabetologica, vol. 46, no. 4, pp. 279–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. P. T. Campbell, A. Deka, E. J. Jacobs et al., “Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men,” Gastroenterology, vol. 139, no. 4, pp. 1138–1146, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Donadon, M. Balbi, F. Valent, and A. Avogaro, “Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 16, no. 24, pp. 3025–3032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. W. S. Yang, P. Va, F. Bray et al., “The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies,” PLoS One, vol. 6, no. 12, Article ID e27326, 2011.
  50. A. N. Dehal, C. C. Newton, E. J. Jacobs, A. V. Patel, S. M. Gapstur, and P. T. Campbell, “Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the cancer prevention study-II nutrition cohort,” Journal of Clinical Oncology, vol. 30, no. 1, pp. 53–59, 2012. View at Publisher · View at Google Scholar
  51. C. H. Tseng, “Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan,” Gut, vol. 60, no. 6, pp. 774–779, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. A. E. Buchs and B. G. Silverman, “Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study,” Metabolism, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. L. T. Chao, C. F. Wu, F. Y. Sung et al., “Insulin, glucose and hepatocellular carcinoma risk in male hepatitis B carriers: results from 17-year follow-up of a population-based cohort,” Carcinogenesis, vol. 32, no. 6, pp. 876–881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. M. L. Irwin, C. Duggan, C. Y. Wang et al., “Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study,” Journal of Clinical Oncology, vol. 29, no. 1, pp. 47–53, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. UK Prospective Diabetes Study (UKPDS) Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. View at Publisher · View at Google Scholar · View at Scopus
  56. UK Prospective Diabetes Study (UKPDS) Group, “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),” The Lancet, vol. 352, no. 9131, pp. 854–865, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Malmberg, “Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus,” British Medical Journal, vol. 314, no. 7093, pp. 1512–1515, 1997. View at Scopus
  58. K. Malmberg, L. Rydén, H. Wedel et al., “FASTTRACK intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity,” European Heart Journal, vol. 26, no. 7, pp. 650–661, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. ORIGIN Trial Investigators, H. C. Gerstein, J. Bosch et al., “Basal insulin and cardiovascular and other outcomes in dysglycemia,” The New England Journal of Medicine, vol. 367, no. 4, pp. 319–328, 2012.
  60. L. G. Mellbin, K. Malmberg, A. Norhammar, H. Wedel, and L. Rydén, “Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study,” Diabetologia, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. B. R. Chaitman, R. M. Hardison, D. Adler et al., “The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment Strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction,” Circulation, vol. 120, no. 25, pp. 2529–2540, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. H. C. Gerstein, W. T. Friedewald, J. B. Buse et al., “Effects of intensive glucose lowering in type 2 diabetes,” New England Journal of Medicine, vol. 358, no. 24, pp. 2545–2559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. ADVANCE Collaborative Group, A. Patel, S. MacMahon et al., “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes,” New England Journal of Medicine, vol. 358, no. 24, pp. 2560–2572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. W. Duckworth, C. Abraira, T. Moritz et al., “Glucose control and vascular complications in veterans with type 2 diabetes,” New England Journal of Medicine, vol. 360, no. 2, pp. 129–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. H. C. Gerstein, M. E. Miller, S. Genuth et al., “Long-term effects of intensive glucose lowering on cardiovascular outcomes,” New England Journal of Medicine, vol. 364, no. 9, pp. 818–828, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Stefansdottir, S. Zoungas, J. Chalmers et al., “Intensive glucose control and risk of cancer in patients with type 2 diabetes,” Diabetologia, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Monami, C. Colombi, D. Balzi et al., “Metformin and cancer occurrence in insulin-treated type 2 diabetic patients,” Diabetes Care, vol. 34, no. 1, pp. 129–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. J. A. Johnson and S. L. Bowker, “Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials,” Diabetologia, vol. 54, no. 1, pp. 25–31, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. S. L. Bowker, Y. Yasui, P. Veugelers, and J. A. Johnson, “Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure,” Diabetologia, vol. 53, no. 8, pp. 1631–1637, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Siebenhofer, J. Plank, A. Berghold et al., “Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.,” Cochrane Database of Systematic Reviews, no. 2, p. CD003287, 2006. View at Scopus
  71. E. Mannucci, M. Monami, and N. Marchionni, “Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis,” Diabetes, Obesity and Metabolism, vol. 11, no. 1, pp. 53–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. M. Monami, N. Marchionni, and E. Mannucci, “Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. A meta-analysis,” Diabetes Research and Clinical Practice, vol. 81, no. 2, pp. 184–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Monami, N. Marchionni, and E. Mannucci, “Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis,” Diabetes, Obesity and Metabolism, vol. 11, no. 4, pp. 372–378, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Drejer, “The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake,” Diabetes/Metabolism Reviews, vol. 8, no. 3, pp. 259–286, 1992. View at Scopus
  75. B. F. Hansen, P. Kurtzhals, A. B. Jensen, A. Dejgaard, and D. Russell-Jones, “Insulin X10 revisited: a super-mitogenic insulin analogue,” Diabetologia, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Drejer, V. Kruse, U. D. Larsen, P. Hougaard, S. Bjorn, and S. Gammeltoft, “Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells,” Diabetes, vol. 40, no. 11, pp. 1488–1495, 1991. View at Scopus
  77. G. Milazzo, L. Sciacca, V. Papa, I. D. Goldfine, and R. Vigneri, “ASPB10 Insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor,” Molecular Carcinogenesis, vol. 18, no. 1, pp. 19–25, 1997. View at Publisher · View at Google Scholar
  78. B. F. Hansen, G. M. Danielsen, K. Drejer et al., “Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency,” Biochemical Journal, vol. 315, no. 1, pp. 271–279, 1996. View at Scopus
  79. K. Staiger, A. M. Hennige, H. Staiger, H. U. Häring, and M. Kellerer, “Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells,” Hormone and Metabolic Research, vol. 39, no. 1, pp. 65–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Liefvendahl and H. J. Arnqvist, “Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I,” Hormone and Metabolic Research, vol. 40, no. 6, pp. 369–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. J. A. Teng, R. L. Hou, D. L. Li, R. P. Yang, and J. Qin, “Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation,” Hormone and Metabolic Research, vol. 43, no. 8, pp. 519–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. D. Weinstein, M. Simon, E. Yehezkel, Z. Laron, and H. Werner, “Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells,” Diabetes/Metabolism Research and Reviews, vol. 25, no. 1, pp. 41–49, 2009. View at Publisher · View at Google Scholar
  83. K. Müller, C. Weidinger, and D. Führer, “Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells,” Diabetologia, vol. 53, no. 5, pp. 1001–1003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Erbel, C. Reers, V. W. Eckstein et al., “Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine,” Diabetes Care, vol. 31, no. 6, pp. 1105–1111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Liu, Y. Li, T. Lin, X. Fan, Y. Liang, and U. Heemann, “High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt,” Diabetes Research and Clinical Practice, vol. 91, no. 2, pp. 177–182, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. P. Kurtzhals, L. Schäffer, A. Sørensen et al., “Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use,” Diabetes, vol. 49, no. 6, pp. 999–1005, 2000. View at Scopus
  87. G. U. Kuerzel, U. Shukla, H. E. Scholtz et al., “Biotransformation of insulin glargine after subcutaneous injection in healthy subjects,” Current Medical Research and Opinion, vol. 19, no. 1, pp. 34–40, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. M. R. Sommerfeld, G. Müller, G. Tschank et al., “In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites,” PLoS ONE, vol. 5, no. 3, Article ID e9540, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Mayer and E. Chantelau, “Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells,” Archives of Physiology and Biochemistry, vol. 116, no. 2, pp. 73–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. E. Mannucci, M. Monami, D. Balzi et al., “Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients,” Diabetes Care, vol. 33, no. 9, pp. 1997–2003, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. R. Ljung, M. TalbÄck, B. Haglund, J. M. Jonasson, S. Gudbjörnsdóttir, and G. Steineck, “Insulin glargine use and short-term incidence of malignancies-a three-year population-based observation,” Acta Oncologica, vol. 50, no. 5, pp. 685–692, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. C. H. Chang, S. Toh, J. W. Lin et al., “Cancer risk associated with insulin Glargine among adult type 2 diabetes patients—a nationwide Cohort study,” PLoS ONE, vol. 6, no. 6, Article ID e21368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. N. E. Morden, S. K. Liu, J. Smith, T. A. Mackenzie, J. Skinner, and M. Korc, “Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients,” Diabetes Care, vol. 34, no. 9, pp. 1965–1971, 2011. View at Publisher · View at Google Scholar
  94. P. Blin, R. Lassalle, C. Dureau-Pournin et al., “Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database,” Diabetologia, vol. 55, no. 3, pp. 644–653, 2012. View at Publisher · View at Google Scholar
  95. R. Ruiter, L. E. Visser, M. P. van Herk-Sukel et al., “Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study,” Diabetologia, vol. 55, no. 1, pp. 51–62, 2012. View at Publisher · View at Google Scholar
  96. S. Suissa, L. Azoulay, S. Dell'Aniello, M. Evans, J. Vora, and M. Pollak, “Long-term effects of insulin glargine on the risk of breast cancer,” Diabetologia, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Lind, M. Fahlén, B. Eliasson, and A. Odén, “The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes,” Prim Care Diabetes, vol. 6, no. 1, pp. 53–59, 2012. View at Publisher · View at Google Scholar
  98. J. Rosenstock, V. Fonseca, J. B. McGill et al., “Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study,” Diabetologia, vol. 52, no. 9, pp. 1971–1973, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. P. D. Home and P. Lagarenne, “Combined randomised controlled trial experience of malignancies in studies using insulin glargine,” Diabetologia, vol. 52, no. 12, pp. 2499–2506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetes Care, vol. 35, no. 6, pp. 1364–1379, 2012. View at Publisher · View at Google Scholar
  101. E. Mannucci, M. Monami, C. Lamanna, F. Gori, and N. Marchionni, “Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 19, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. K. K. Ray, S. R. K. Seshasai, S. Wijesuriya et al., “Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials,” The Lancet, vol. 373, no. 9677, pp. 1765–1772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. T. N. Kelly, L. A. Bazzano, V. A. Fonseca, T. K. Thethi, K. Reynolds, and J. He, “Systematic review: glucose control and cardiovascular disease in type 2 diabetes,” Annals of Internal Medicine, vol. 151, no. 6, pp. 394–403, 2009. View at Scopus
  104. Control Group, F. M. Turnbull, C. Abraira et al., “Intensive glucose control and macrovascular outcomes in type 2 diabetes,” Diabetologia, vol. 52, no. 11, pp. 2288–2298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. B. Hemmingsen, S. S. Lund, C. Gluud et al., “Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials,” British Medical Journal, vol. 343, Article ID d6898, 2011. View at Publisher · View at Google Scholar
  106. B. Hemmingsen, S. S. Lund, C. Gluud, A. Vaag, T. Almdal, and J. Wetterslev, “Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD008143, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Weng, Y. Li, W. Xu et al., “Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial,” The Lancet, vol. 371, no. 9626, pp. 1753–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. P. D. Home, A. Fritsche, S. Schinzel, and M. Massi-Benedetti, “Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine,” Diabetes, Obesity and Metabolism, vol. 12, no. 9, pp. 772–779, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. A. E. Pontiroli, L. Miele, and A. Morabito, “Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis,” Diabetes, Obesity and Metabolism, vol. 14, no. 5, pp. 433–446, 2012. View at Publisher · View at Google Scholar
  110. G. B. Bolli, P. Lucidi, F. Porcellati, and C. G. Fanelli, “Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes.,” Diabetes care, supplement 2, pp. S220–224, 2011. View at Scopus
  111. B. Hemmingsen, L.L. Christensen, J. Wetterslev et al., “Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses,” British Medical Journal, vol. 344, no. 7853, Article ID e1771, 2012. View at Publisher · View at Google Scholar
  112. R. J. Dowling, S. Niraula, V. Stambolic, and P. J. Goodwin, “Metformin in cancer: translational challenges,” Journal of Molecular Endocrinology, vol. 48, no. 3, pp. R31–R43, 2012. View at Publisher · View at Google Scholar
  113. K. Horvath, K. Jeitler, A. Berghold et al., “Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.,” Cochrane Database of Systematic Reviews, no. 2, p. CD005613, 2007. View at Scopus
  114. S. G. Swinnen, A. C. Simon, F. Holleman, J. B. Hoekstra, and J. H. Devries, “Insulin detemir versus insulin glargine for type 2 diabetes mellitus.,” Cochrane Database of Systematic Reviews, no. 7, p. CD006383, 2011. View at Scopus
  115. A. Dejgaard, H. Lynggaard, J. Råstam, and M. Krogsgaard Thomsen, “No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis,” Diabetologia, vol. 52, no. 12, pp. 2507–2512, 2009. View at Publisher · View at Google Scholar · View at Scopus